Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 3, 2001, Pages 411-416

  Fakheri, H ^a   Malekzadeh, R ^a   Merat, S ^a   Khatibian, M ^a   Fazel, A ^b   Alizadeh, B Z ^a   Massarrat, S ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CIMETIDINE; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPED COUNTRY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; IRAN; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PENICILLINS; TREATMENT OUTCOME;

EID: 0035123052     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00931.x     Document Type: Article

References (51)

1. Consensus development panel on Helicobacter pylori ulcer disease. Helicobacter pylori in peptic disease. NIH Consensus conference
2. Does eradication of Helicobacter pylori alone heal duodenal ulcers?
3. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States
4. Antibiotic-resistant H. pylori infection and its treatment
5. Challenges to therapy in the future
6. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong
7. Strategy for treatment of Helicobacter pylori infection in adults II. Practical policy 2000
8. One week bismuth + metronidazole + amoxicillin (BMA) with ranitidine (RAN) versus two weeks BMA without RAN versus 2 weeks. BMA + RAN for HP eradication: A randomized single blind controlled study
9. Randomized controlled trial comparing two weeks modified quadruple (OME + CBS + TET + CLA) to two and three weeks ranitidine + triple (CBS + MET + TET) therapy for Hp eradication in duodenal ulcer
10. Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy compromising omeprazole and amoxicillin
11. Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori and prevention of ulcer replace over a 1 year follow-up period: A prospective, randomized, controlled study
12. Effect of two different doses of metronidazole and tetracycline in classic triple therapy on eradication of H. pylori and its metronidazole resistant strains
13. Susceptibility of various strains of Helicobacter pylori to selected agents
14. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones
15. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil
16. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan
17. Furazolidone versus metronidazole in quadruple therapy for eradication or Helicobacter pylori in duodenal ulcer disease
18. Effect of furazolidone bismuth subcitrate and amoxicillin for eradication of Helicobacter pylori in Iran
19. Furazolidone combination therapies for Helicobacter pylori infection in the United States
20. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer
21. Furazolidone, amoxicilline, bismuth triple therapy for Helicobacter pylori infection
22. 14C urea breath test for detection of Helicobacter pylori
23. Treatment of Helicobacter pylori infection
24. Effectiveness of H. pylori treatment regimens in clinical practice: A community based outcomes study
25. Resistance of Helicobacter pylori to antibiotics
26. Metronidazole and clarithromycin resistance among HP isolates from a large hospital in the United State
27. Metronidazole resistance is high in Korea and Columbia and appears to be rapidly increasing in the U.S.
28. Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection
29. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of American College of Gastroenterology
30. Clarithromycin, tetracycline, and bismuth: A new nonmetronidazole therapy for Helicobacter pylori infection
31. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: The HERO study
32. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group
33. Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: Testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication
34. Effect of acid suppression on efficacy of treatment for H. pylori infection
35. Elimination of Helicobacter pylori under treatment with omeprazole
36. Treatment of Helicobacter pylori infection
37. Effectiveness of 10 days omeprazole + clarithromycin + tinidazole (OCT) in patients who previously failed metronidazole-based therapy
38. Sevenday treatment for Helicobacter pylori infection: Ranitidine, bismuth citrate plus clarithromycin and tetracycline
39. Eradication of Helicobacter pylori by a 1-week course of ranitidine + amoxicillin + clarithromycin
40. Randomized clinical trial comparing two one-week triple therapy regimens for the eradication of Helicobacter pylori
41. Eradication of Helicobacter pylori with clarithromycin and omeprazole
42. Absorption, distribution, metabolism and excretion of furazolidone. A review of the literature
43. Treatment of peptic ulcer disease with furazolidone
44. Double-blind short-term trial of furazolidone in peptic ulcer
45. Furazolidone in peptic ulcer
46. In vitro sensitivity of Campylobacter pyloridis to furazolidone
47. In vivo susceptibility of Campylobacter pylori
48. In vitro selection of resistant Helicobacter pylori
49. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection
50. Twice daily, 10-days triple therapy with omeprazole amoxicillin and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease
51. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori